Overview

Enhanced approaches for using plant-derived molecules as a more promising cancer treatment alternative, with lower costs and fewer side effects Plant-derived Anticancer Drugs discusses the current scenario of cancer, the limitations of synthetic drugs, and the potential of plant-derived molecules in cancer treatment, highlighting a variety of approaches, such as biodegradable nano and quantum dot-based materials, that enhance the therapeutic efficacy of plant-derived molecules to improve solubility, applicability, target-specific delivery, and overall efficacy. The book begins by discussing the preclinical and clinical utilization of synthetic drugs in cancer therapy, highlighting their mechanisms of action, therapeutic outcomes, limitations, and future perspectives. The book then provides a snapshot of the major drugs approved by the FDA which have historically served as the cornerstone of center treatment, and provides a clinical evidence-based analysis of their survival outcomes. Next, the current role, acceptance, advancements, and challenges of using plant-derived molecules in cancer therapy are reviewed. Contributed to by international experts in the field, Plant-derived Anticancer Drugs continues to cover sample topics including: Advancements in anti-cancer drug development due to genomics, biotechnology, and systems biology Integrative approaches which leverage the cytotoxic precision of synthetic drugs alongside the multitargeted and often less toxic nature of phytochemicals Optimization of phytochemicals with high anticancer potential to reduce drug discovery timelines and associated costs Integration of Artificial Intelligence (AI) and plant-derived bioactive compounds Ability of plant-derived molecules and herbal formulations to target multiple pathways involved in cancer progression, such as cell proliferation, apoptosis, angiogenesis, and metastasis Plant-derived Anticancer Drugs is a completely comprehensive and up-to-date reference on the subject, ideal for natural products chemists, medicinal chemists, biochemists, and cancer researchers in academia and industry. The book is also valuable reading for graduates and undergraduates studying nanotechnology, phytochemistry, pharmacology, oncology, and toxicology.

Full Product Details

Author:   Vipendra Kumar Singh (India Institute of Technology Mandi, India) ,  Ankit Kumar Singh (Lalit Narayan Mithila University, India) ,  Neha Garg (Banaras Hindu University, India)
Publisher:   John Wiley & Sons Inc
Imprint:   John Wiley & Sons Inc
ISBN:  

9781394300563

ISBN 10:   1394300565
Pages:   464
Publication Date:   07 November 2025
Audience:   College/higher education ,  Professional and scholarly ,  Undergraduate ,  Postgraduate, Research & Scholarly
Format:   Hardback
Publisher's Status:   Active
Availability:   Out of stock  
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

List of Contributors xvii Preface xxi 1 Utilization of Synthetic Drugs in Cancer: Preclinical and Clinical-based Evidence 1 Sandeep Vaidya, Avadh Biharee, Arpita Yadav, Arun Kumar Sharma, Akhlesh Kumar Jain, Suresh Thareja, and Mayank Kumar Singh 1.1 Introduction 1 1.2 Synthetic Pharmaceutical Anticancer Drugs 8 1.3 Challenges Faced in Early Drug Development 17 1.4 Conclusion 20 2 United States and European Union Regulations: Approved Treatment Modalities for Managing Cancer 29 Avadh Biharee, Khushi Gupta, Arpita Yadav, Shivam Kumar kori, Sudha Bhartiya, Kashif sheikh, Sandeep Vaidya, Sushil K. Kashaw, Suresh Thareja, and Mayank Kumar Singh 2.1 Introduction 29 2.2 FDA Strategies for Drug Approval in the United States 31 2.3 EMA Approach for Drug Approval in the EU 35 2.4 Approved Treatment Modalities for Cancer Care 38 2.5 Quality Control in Cancer Treatment 43 2.6 Regulatory Frameworks Involved in Drug Approval Process 44 2.7 Challenges Associated in Drug and Devices Regulation and Approval 52 2.8 Conclusion 53 3 Survival Rate and Associated Side Effects of Synthetic Drugs in Cancer Patients: A Shred of Clinical Evidence 63 Arpita Yadav, Arun Kumar Sharma, Kishan Kumar Pandey, Anu Chaudhary, Avadh Biharee, Sandeep Vaidya, Suresh Thareja, and Mayank Kumar Singh 3.1 Introduction 63 3.2 Synthetic Drugs in Cancer Treatment 65 3.3 The Evolution of Chemotherapeutic Agents from Alkylators to Modern Drugs 66 3.4 Cancer Survival Rates: Challenges and Emerging Trends in Treatment and Diagnosis 68 3.5 Deleterious Effects of Chemotherapeutic Agents and Their Management Strategies 72 3.6 Side Effects of Synthetic Drugs 74 3.7 Clinical Evidence of Side Effects 76 3.8 Resistance and Recurrence 76 3.9 Future Directions of Synthetic Drugs Against Various Types of Cancer 77 3.10 Conclusion 78 4 Global Perspectives on Plant-derived Cancer Therapies 91 Sayanta Sarkar and Poorwa Awasthi 4.1 Introduction 91 4.2 Phytochemicals in Cancer Therapies 92 4.3 Phytochemicals in Drug-resistant Cancers 103 4.4 Plant-based Nanomedicines in Cancer Therapies 103 4.5 Conclusion and Future Perspectives 104 5 Integrative Approaches: Combining Conventional and Plant-derived Cancer Therapies 119 Poorwa Awasthi, Shweta Goyal, and Sayanta Sarkar 5.1 Introduction 119 5.2 Conventional Cancer Therapies: Achievements and Limitations 120 5.3 Plant-derived Compounds in Cancer Therapy 124 5.4 Advantages of Natural Products 125 5.5 Synergistic Potential of Combination Therapies 128 5.6 Challenges and Future Perspectives 140 5.7 Conclusion 142 6 Phytochemical Drugs in Cancer: Therapeutic Interventions and Opportunities 159 Archana Kumari, Shankar Suman, and Shivam Priya 6.1 Introduction 159 6.2 Plant-derived Compounds in Cancer Therapy 160 6.3 Mechanisms of Action of Plant-derived Compounds 162 6.4 Nanotechnology in Enhancing Plant-derived Compounds 164 6.5 Clinical Trials and Research on Plant-derived Anticancer Compounds 165 6.6 Challenges and Future Directions in Plant-derived Cancer Therapies 166 6.7 Advanced Applications of Bioinformatics in Plant-based Drug Discovery 168 6.8 Case Studies of Successful Plant-derived Cancer Therapies 169 6.9 Future Perspectives and Integration into Clinical Oncology 171 6.10 Conclusion and Future Directions 172 7 Plant-derived Anticancer Molecules as Novel Outlook in the Management of Cancers: An In silico and Pharmacophore-based Approaches 183 Surya Venkateswara Prabhu Ratnam Kesanapalli, Babli K. Jha, and Laxmi Devi 7.1 Introduction 183 7.2 Historical Perspective 184 7.3 Key Discoveries of Plant-derived Anticancer Compounds 184 7.4 Phytochemicals with Anticancer Properties 185 7.5 Computational Approaches in Phytochemical Research 188 7.6 Novel Therapeutic Approaches 193 7.7 Challenges and Future Directions 196 7.8 Bioavailability Issues 196 7.9 Regulatory Hurdles 196 7.10 Advancements in Computational Power and Algorithms 197 7.11 Conclusion 200 8 Plant-derived Molecules and Herbal Formulation for Cancer Treatment: in vitro and in vivo Evidence 209 Surya Venkateswara Prabhu Ratnam Kesanapalli, Babli K. Jha, and Laxmi Devi 8.1 Introduction 209 8.2 Historical Use of Herbal Remedies in Cancer 210 8.3 Natural Compounds with Anticancer Properties 211 8.4 Mechanism of Action 215 8.5 Natural Remedies in Cancer Treatment 216 8.6 Phototherapeutic Approaches in Oncology Care 218 8.7 Methodological Approaches 220 8.8 In vivo Studies (Animal Models) 222 8.9 Ex Vivo and 3D Models 224 8.10 Clinical Trials and Translational Research 224 8.11 Nanotechnology-based Delivery Systems 224 8.12 Experimental Validation of Computational Predictions 224 8.13 Key Findings 228 8.14 Challenges and Future Directions 228 8.15 Future Studies and Clinical Trials 229 8.16 Conclusion 229 9 Globalization of Plant-derived Molecules Against Progression and Metastasis of Cancer in the Last Few Decades 239 Kavita, Praveen Kumar, Shikha Singh, and Neha Garg 9.1 Introduction 239 9.2 Plant-derived Molecules in Cancer 240 9.3 Conclusion and Future Perspectives 263 10 Quantum Dots for Targeted Delivery of Plant-derived Anticancer Biomolecules 279 Rashmi P. Sharma 10.1 Introduction 279 10.2 Quantum Dots: A Promising Nanomaterial 283 10.3 Cellular Delivery of Cancer-targeting QDs 286 10.4 Recent Developments in Using QD-based Targeted Drug Delivery 288 10.5 Challenges and Future Perspectives 297 10.6 Conclusions 299 11 Future of Artificial Intelligence and Plant-derived Molecules in Cancer Therapy 313 Jyotika Rajawat, Shreya Prakash, and Poorwa Awasthi 11.1 Introduction 313 11.2 Plant-derived Molecules in Cancer Therapy 315 11.3 Natural Plant Extracts with Potential as Anticancer Agents 319 11.4 AI in Cancer Diagnosis and Treatment 323 11.5 Role of AI in Advancing Plant-derived Molecules for Cancer Therapy 327 11.6 Future Perspectives 332 12 Scientific Basis of Plant-derived Quantum Dots for Enhancing the Therapeutic Efficacy in Cancer 341 Lucky Kumari, Shashi Kumar, Chandramani Batsh, Shachi Mishra, and Akanksha Upadhyay 12.1 Introduction 341 12.2 Classification of QDs 344 12.3 Synthesis of Plant-derived QDs 346 12.4 Plant-derived QDs in Cancer Diagnosis and Therapy 352 12.5 Therapeutic Efficacy 354 12.6 Conclusion and Future Perspectives 359 13 Clinical Trials of Plant-derived Molecules and Herbal Formulations for the Treatment of Cancers 367 Ankur Kumar 13.1 Introduction 367 13.2 Clinical Trials of Curcumin 368 13.3 Clinical Trials of Catechin and Tea 373 13.4 Clinical Trials of Quercetin 379 13.5 Clinical Trials of Ginseng Extract 380 13.6 Clinical Trials of Genistein 381 13.7 Clinical Trial of Resveratrol 382 13.8 Clinical Trials of Sulforaphane 383 13.9 Clinical Trials of Berberine 384 13.10 Clinical Trials of Lycopene 385 13.11 Clinical Trials of Chinese Herbal Formulation 386 13.12 Clinical Trials of Other Herbal Formulation 393 13.13 Clinical Trials of Rutin 395 13.14 Clinical Trials of Betulinic Acid 395 14 Preclinical and Clinical Trials of Plant-derived Nanoparticles in Different Cancers 401 Vivek Kumar Pandey and Shailja Tripathi 14.1 Introduction 401 14.2 Synthesis of Plant-derived Nanoparticles 402 14.3 PDNPs in Cancers 405 14.4 PDNPs in Other Metabolic Diseases 411 14.5 Challenges and Future Directions 413 References 414 Index 427

Reviews

Author Information

Vipendra Kumar Singh, PhD is a senior postdoctoral fellow in the School of Biosciences and Bioengineering at the Indian Institute of Technology Mandi, Himachal Pradesh, India. Ankit Kumar Singh, PhD works as an Assistant Professor at the University Department of Botany Lalit Narayan Mithila University, Darbhanga, Bihar, India. Neha Garg, PhD is an Assistant Professor at the Institute of Medical Sciences, Department of Medicinal Chemistry, Banaras Hindu University in India.

Tab Content 6

Author Website:  

Countries Available

All regions